Table 1.
Treatment characteristics | Treatment | p-value | ||||
---|---|---|---|---|---|---|
Guselkumab | Risankizumab | Tildrakizumab | All treatments | |||
Total number of treatments/patients | 127 | 55 | 15 | 197 | ||
Characteristic at start of treatment | Number (%) of females | 44 (34.6) | 19 (34.5) | 4 (26.7) | 67 (34.0) | 0.891 |
Mean age (SD) | 46.0 (14.2) | 47.9 (11.6) | 45.9 (14.1) | 46.5 (13.5) | 0.668 | |
Mean PASI (SD) in biologic naïve patients | 9.63 (6.59) | 11.13 (6.67) | 11.67 (11.08) | 10.25 (7.23) | 0.545 | |
Mean PASI (SD) in biologic non-naïve patients | 7.80 (7.52) | 9.13 (8.10) | 9.13 (5.22) | 8.01 (7.44) | 0.700 | |
Number (%) of patients with PASI ≤ 3 | 37 (29.1) | 12 (21.8) | 3 (20.0) | 52 (26.4) | 0.496812 | |
Number (%) of cycles in patients with arthritis | 31 (24.4) | 19 (34.5) | 1 (6.7) | 51 (25.9) | 0.077 | |
Mean weight in kg (SD) | 92.0 (19.2) | 88.9 (13.4) | 94.4 (11.8) | 91.3 (17.4) | 0.736 | |
Mean BMI (SD) | 30.0 (6.5) | 29.3 (4.4) | 29.9 (2.3) | 29.8 (5.6) | 0.914 | |
Number (%) of patient with the last previous biologic treatment | None | 54 (42.5) | 29 (52.7) | 11 (73.3) | 94 (47.7) | 0.068 |
TNF-alpha | 14 (11.0) | 6 (10.9) | 0 (0) | 20 (10.2)+ | ||
IL-12/23 | 33 (26.0) | 5 (9.1) | 2 (13.3) | 40 (20.3)* | ||
IL-17 | 26 (20.5) | 15 (27.3) | 2 (13.3) | 43 (21.8)# | ||
Number (%) of previous biologic therapies | 1 | 41 (55.4) | 13 (50.0) | 2 (50.0) | 56 (53.8) | 0.767 |
2 | 14 (18.9) | 8 (30.8) | 1 (25.0) | 23 (22.1) | ||
≥ 3 | 19 (25.7) | 5 (19.2) | 1 (25.0) | 25 (24.0) |
Analysis of variances and chi-square test did not reveal differences in allocation to treatment regarding sex, age, PASI, psoriatic arthritis, or (type of) previous biologic exposure. Chi-square test results revealed that a previous treatment with TNF-alpha and IL-12/23 inhibitors were the first biologic treatments for a significantly higher proportion of patients (p = 0.000778).
+Seven patients (35.0%) were biologic-non-naïve when treated with TNF-alpha inhibitors.
*Ten patients (25.0%) were biologic-non-naïve when treated with IL-12/23 inhibitors.
#Twenty-eight patients (65.1%) were biologic-non-naïve when treated with IL-17 inhibitors.
BMI, body mass index; IL, interleukin; PASI, Psoriasis Area and Severity Index; SD, standard deviation; TNF, tumour necrosis factor.